Amgen’s Stelara Biosimilar Produces Positive Phase III Results
Firm’s ABP 654 Ustekinumab Candidate Is Also Being Lined Up For Interchangeability
Executive Summary
Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.
You may also be interested in...
Competition Intensifies As Access Increases For US Biosimilars
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.
Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone
Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.
Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.